Wall Street analysts forecast that CEL-SCI Co. (NYSE:CVM – Get Rating) will announce earnings of ($0.16) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for CEL-SCI’s earnings. CEL-SCI reported earnings of ($0.20) per share in the same quarter last year, which would suggest a positive year over year growth rate of 20%. The business is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that CEL-SCI will report full-year earnings of ($0.49) per share for the current year. For the next financial year, analysts anticipate that the firm will post earnings of $0.91 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow CEL-SCI.
Separately, StockNews.com started coverage on CEL-SCI in a report on Thursday, March 31st. They issued a “sell” rating on the stock.
CEL-SCI Company Profile (Get Rating)
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
- Get a free copy of the StockNews.com research report on CEL-SCI (CVM)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.